Novel Anti-Angiogenic Drugs for Cancer Therapy

描述：(申请人提供) 血管生成，即新血管的形成，是进步的关键 肿瘤的生长和转移。旨在抑制肿瘤血管生成的治疗方法 (和通过营养匮乏而缩小的肿瘤)在 癌症治疗，因为他们避免了与标准 化疗或放射治疗，即肿瘤的最终生长对 治疗剂，由其产生的衰弱的全身副作用 化疗和放射治疗导致的继发性癌症。这个 特异性抑制血管生成的生物制剂的产生 体内促肿瘤因子的活性可能是一种极好的 创造新的癌症治疗药物的手段。第一阶段的具体目标 本应用主要有：1)制备和纯化定向的单抗 针对一种特定的血管生成因子，该因子被强烈地牵连为 肿瘤生长的基本调节因子，以及2)筛选这些抗体 因为动物有能力阻止靶向因子的活动。在……里面 第二阶段，被确认为靶向因子肿瘤抑制因子的抗体 促进生长的活性将被调整为临床用于癌症 治疗剂。 建议的商业应用： 癌症是美国第二大死亡原因，它的医疗费用是 远远超过1000亿美元。实体瘤占癌症的大多数，困扰着300多万人。 每年造成50多万人死亡。医疗保健市场为抗击 血管生成抗癌药在传统癌症治疗中具有非常重要的意义 往往导致耐药的癌细胞，并造成严重的副作用。 合作机构：

DESCRIPTION: (provided by applicant) Angiogenesis, formation of new blood vessels, is essential for progressive tumor growth and metastasis. Therapies aimed at inhibiting tumor angiogenesis (and shrinking tumors through nutrient starvation) hold great promise in cancer treatment because they avoid major problems associated with standard chemo or radiotherapy, i.e., the eventual growth of tumors resistant to the therapeutic agent, the debilitating systemic side effects engendered by chemotherapy, and the generation of secondary cancers by radiotherapy. The generation of biological agents that specifically suppress the angiogenic activity of tumor-promoting factors in the body is potentially an excellent means of creating novel cancer therapy agents. The specific aims of Phase I of this application are 1) to generate and purify monoclonal antibodies directed against a particular angiogenic factor that is strongly implicated as an essential regulator of tumor growth, and 2) to screen these antibodies in animals for their ability to block the activity of the targeted factor. In Phase II, antibodies identified as suppressors of the targeted factor's tumor growth-promoting activity would be adapted for clinical use as cancer therapeutic agents. PROPOSED COMMERCIAL APPLICATION: Cancer is the second leading cause of mortality in the U.S., and its health care costs are well over $100 billion. Solid tumors comprise the majority of cancers, afflict over 3 million people, and cause over a half million deaths annually. The health care market for anti- angiogenesis anti-cancer agents in very significant because conventional cancer therapy often results in resistant cancer cells, and causes serious side effects. COLLABORATING INSTITUTIONS: